| Not Yet Recruiting | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma NCT07529808 | BigHat Biosciences, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advan NCT07486310 | Guangdong Provincial People's Hospital | Phase 2 |
| Not Yet Recruiting | A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Thi NCT07371871 | Anhui Provincial Cancer Hospital | N/A |
| Recruiting | Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastri NCT07537348 | Qilu Hospital of Shandong University | Phase 2 |
| Recruiting | Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen V NCT07298200 | Jia Wei | Phase 1 |
| Recruiting | Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers NCT07259226 | UNICANCER | Phase 2 |
| Recruiting | Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastat NCT07315854 | Beijing Friendship Hospital | Phase 2 |
| Not Yet Recruiting | MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma NCT07144995 | Sun Yat-sen University | — |
| Recruiting | Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Juncti NCT07102901 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Recruiting | Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursin NCT07405931 | Ulsan University Hospital | N/A |
| Recruiting | PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer NCT07294664 | The First Affiliated Hospital of Zhengzhou University | Phase 2 |
| Recruiting | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors NCT06769425 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases NCT06940921 | Zhang Tao | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeri NCT06706895 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Zolbetuximab Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer NCT06767449 | Yonsei University | — |
| Recruiting | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advan NCT06585488 | BeiGene | Phase 1 |
| Recruiting | A Multi-center Real-world Efficacy and Safety of Trastuzumab-deruxtecan in Advanced Gastric Cancer NCT06767436 | Yonsei University | — |
| Not Yet Recruiting | The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastri NCT06592287 | Xianglin Yuan | Phase 1 / Phase 2 |
| Not Yet Recruiting | Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer NCT06486545 | Hunan Cancer Hospital | N/A |
| Not Yet Recruiting | Neoantigen Reactive T Cells c for Chinese Patients With Advanced Gastric Cancer NCT06432075 | First Affiliated Hospital of Wenzhou Medical University | EARLY_Phase 1 |
| Recruiting | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors NCT06157892 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Recruiting | Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer NCT06346093 | Changhai Hospital | N/A |
| Unknown | Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanc NCT06169410 | Yang Jianjun, PhD | Phase 4 |
| Unknown | Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy NCT05649163 | Shen Lin | — |
| Suspended | IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing A NCT05076591 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 1 |
| Completed | Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping. NCT06376773 | Fujian Medical University | — |
| Recruiting | First-Line and Neoadjuvant Immunotherapy for Gastric Cancer NCT06727981 | Qilu Hospital of Shandong University | — |
| Recruiting | A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma NCT04799548 | Shanghai Zhongshan Hospital | Phase 2 |
| Unknown | IMC001 for Clinical Research on Advanced Digestive System Malignancies NCT05028933 | Zhejiang University | Phase 1 |
| Unknown | Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC NCT04890392 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Unknown | A Randomized Controlled Trial of Integrated Early Palliative Care for Advanced Gastric Cancer Patients NCT05584592 | Yonsei University | N/A |
| Completed | Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advan NCT04195828 | Fujian Medical University | Phase 2 |
| Unknown | Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer NCT04286711 | China Medical University, China | Phase 1 / Phase 2 |
| Unknown | A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Diss NCT04797923 | Gangnam Severance Hospital | Phase 2 |
| Unknown | Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer NCT04182724 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Unknown | Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and NCT04385641 | Shandong Golden Brick Biotechnology Co., Ltd. | N/A |
| Unknown | Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer NCT03954756 | Henan Cancer Hospital | Phase 2 |
| Active Not Recruiting | Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cance NCT03579784 | Do-Youn Oh | Phase 2 |
| Completed | Lenvatinib and Pembrolizumab Simultaneous Combination Study NCT03609359 | National Cancer Center Hospital East | Phase 2 |
| Unknown | Laparoscopic Versus Open Gastrectomy for Elderly Local Advanced Gastric Cancer Patients NCT03564834 | Peking University | Phase 2 |
| Unknown | A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor NCT03393416 | HRYZ Biotech Co. | Phase 1 |
| Withdrawn | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer NCT03554395 | Fuda Cancer Hospital, Guangzhou | Phase 2 |
| Unknown | Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer NCT03286244 | AnewPharma | Phase 1 |
| Unknown | Comparison of Ability of pCLE and WLE for Diagnosis and Cancer Tissue Acquisition in Advanced Gastric Cancer A NCT03449966 | Yonsei University | N/A |
| Completed | Bioinformation Therapy for Gastric Cancer NCT03350477 | Fuda Cancer Hospital, Guangzhou | Phase 2 / Phase 3 |
| Completed | A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) NCT03223376 | Hutchison Medipharma Limited | Phase 3 |
| Unknown | Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer NCT03137004 | Fujian Cancer Hospital | Phase 2 |
| Unknown | Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer NCT03255811 | DongMa | N/A |
| Completed | A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer NCT02935634 | Bristol-Myers Squibb | Phase 2 |
| Completed | Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 NCT02952729 | Mersana Therapeutics | Phase 1 |
| Unknown | Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer NCT02873520 | Ningbo Cancer Hospital | Phase 1 / Phase 2 |
| Terminated | A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced Neuropat NCT02560740 | SMR Biotech Co., Ltd. | N/A |
| Terminated | A Phase II Trial of Adjuvant Chemotherapy With S-1 Plus Oxaliplatin for Locally Advanced Gastric Cancer NCT01946061 | Yonsei University | Phase 2 |
| Completed | Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA NCT02451956 | Samsung Medical Center | Phase 2 |
| Completed | Potential Advantages of Robotic Total Gastrectomy in Advanced Middle-Upper Gastric Cancer: A Multicenter Prope NCT06941168 | Fujian Medical University | — |
| Unknown | The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer NCT02038621 | The Second People's Hospital of Sichuan | Phase 2 |
| Unknown | Clinical Study on the Harvesting Lymph Nodes With Carbon Nanoparticles for Advanced Gastric Cancer NCT02123407 | Peking University | Phase 3 |
| Unknown | Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer NCT02072317 | Fudan University | Phase 2 |
| Completed | FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer NCT01503372 | Charite University, Berlin, Germany | Phase 2 |
| Terminated | Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients NCT01402401 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced NCT01472250 | Peking University | — |
| Completed | A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcin NCT01248403 | Krankenhaus Nordwest | Phase 3 |
| Unknown | Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer NCT01206218 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 / Phase 3 |
| Completed | PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer NCT01152853 | Seoul National University Hospital | Phase 2 |
| Completed | Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric NCT01471470 | Asan Medical Center | Phase 2 |
| Completed | Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer NCT01084330 | Novartis Pharmaceuticals | Phase 2 |
| Completed | RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD0 NCT01049620 | Asan Medical Center | Phase 1 |
| Completed | Venous Thromboembolism in Advanced Gastric Cancer Patients NCT01047618 | Asan Medical Center | — |
| Unknown | Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stoma NCT01015339 | Peking University | Phase 3 |
| Unknown | Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Ca NCT00992199 | Fudan University | Phase 2 |
| Completed | Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gas NCT00879333 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer NCT00842244 | Pfizer | Phase 1 |
| Unknown | Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gast NCT00845884 | Rabin Medical Center | Phase 1 / Phase 2 |
| Unknown | Efficacy Study of TKcell in Advanced Gastric Cancer NCT00854854 | Binex | Phase 1 / Phase 2 |
| Completed | Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS NCT00915382 | Asan Medical Center | Phase 3 |
| Completed | Laparoscopic Gastrectomy for Advanced Gastric Cancer NCT01441336 | Seoul National University Bundang Hospital | Phase 2 |
| Completed | Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer NCT01238055 | Samsung Medical Center | Phase 2 |
| Completed | Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric C NCT02071043 | Shanghai Zhongshan Hospital | Phase 2 |
| Completed | Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer NCT00842491 | Peking University | Phase 2 |
| Completed | Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer NCT00821990 | Samsung Medical Center | Phase 3 |
| Completed | Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Adva NCT00743964 | Samsung Medical Center | Phase 2 |
| Completed | Paclitaxel and Irinotecan in Advanced Gastric Cancer NCT01136031 | Seoul National University Hospital | Phase 1 / Phase 2 |
| Completed | Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Canc NCT01042782 | Krankenhaus Nordwest | Phase 1 |
| Completed | Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP NCT00565370 | Asan Medical Center | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer NCT00519324 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. NCT00428220 | Pfizer | N/A |
| Completed | Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplati NCT00976768 | Asan Medical Center | Phase 2 |
| Completed | A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) NCT01851941 | Seoul National University Hospital | Phase 2 |
| Completed | Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer NCT02142322 | Seoul National University Hospital | Phase 2 |